PhD Scientific Days 2021

PH_II_L: Pharmaceutical Sciences II. Lectures

Ischemic helium conditioning increases cardiac fibroblast migration which is not propagated via soluble factors or extracellular vesicles

Előadó neve

Dr. Csenger, Kovácsházi

Előadó munkahelye

Semmelweis University, department of Pharmacology and Pharmacotherapy

Előadó telefonszáma

+36 20 998 7894

Előadó e-mail címe

kovacshazi.csenger@med.semmelweis-univ.hu

Az előadás címe

Ischemic helium conditioning increases cardiac fibroblast migration which is not propagated via soluble factors or extracellular vesicles

Szerző(k) neve és munkahelye

Csenger Kovácsházi2,†, Marek Jelemenský1,† , Kristína Ferenczyová1 , Monika Hofbauerová3,4, Bernadett Kiss2, Éva Pállinger5, Edit Buzás5, Ágnes Kittel6, Viktor Nabil Sayour2, Anikó Görbe2,7, Csilla Pelyhe2, Szabolcs Hambalkó2, Miroslav Barančík1, Péter Ferdinandy2,7, Monika Barteková1,8, Zoltán Giricz2,7


1 Institute for Heart Research, Centre of Experimental Medicine, Slovak Academy of Sciences, 84104 Bratislava, Slovakia; marek.jelemensky@savba.sk (M.J.); kristina.ferenczyova@savba.sk (K.F.); miroslav.barancik@savba.sk (Mi.B.); monika.bartekova@savba.sk (M.B.)
2 Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest, Hungary; giricz.zoltan@med.semmelweis-univ.hu
3 Institute of Physics, Slovak Academy of Sciences, Dúbravskáa cesta 9, SK-84511 Bratislava, Slovakia; monika.hofbauerova@savba.sk (M.H.)
4 Centre of excellence for advanced material application, Slovak Academy of Sciences, Dúbravská cesta 9, SK-84511 Bratislava, Slovakia; monika.hofbauerova@savba.sk (M.H.)
5 Semmelweis University, Department of Genetics, Cell- and Immunobiology, Budapest, Hungary; e-mail@e-mail.com
6 Institute of Experimental Medicine, Eötvös Loránd Research Network, Budapest, Hungary
7 Pharmahungary ltd., Szeged, Hungary; e-mail@e-mail.com
8 Institute of Physiology, Faculty of Medicine, Comenius University in Bratislava, 81372 Bratislava, Slovakia; monika.bartekova@savba.sk
† These authors contributed equally

Bemutatás módja

Szóbeli

Szekció

Pharmaceutical Sciences II. Lectures

Language of the presentation

Hungarian

Preferred session

Pharmaceutical Sciences

Összefoglaló szövege

Introduction: Helium inhalation and ischemic conditioning induce cardioprotection against ischemia/reperfusion injury, of which cellular mechanism is not fully elucidated. Extracellular vesicles (EVs) are cell-derived, nano-sized membrane vesicles which play role in cardioprotective mechanisms, but their function in helium-conditioning (HeC) has not been studied, yet.
Aims: We investigate how HeC affects cardiac fibroblasts, and if their HeC-induced EVs or other secreted factors propagate cardioprotection between cardiac cells.
Methods: Neonatal rat cardiac fibroblasts (NRCF) were exposed to glucose deprivation and HeC rendered by four cycles of 95% helium + 5% CO2 for one hour, followed by one hour normoxic condition. 40 hours after HeC NRCF activation was analyzed with Western blot (WB) and migration assays. From cell supernatant, large extracellular vesicles (lEVs) were isolated with differential centrifugation and analyzed with WB and nanoparticle tracking analysis. Supernatant from HeC-treated NRCF was transferred to naïve NRCF and immortalized human umbilical vein endothelia cells (HUVEC/TERT2) and migration and angiogenesis assay was performed.
Result: HeC accelerated the migration of NRCFs. Meanwhile, HeC did not increase the expression of markers of fibroblast activation, or secretion of lEVs from NRCF. HeC tend to decrease lEV secretion of NRCFs, but supernatant of HeC or CTRL NRCF did not accelerate the migration of naïve NRCF or affect angiogenic potential of HUVEC/TERT2.
Conclusion: Since HeC increased the migration of NRCF but did not induce myofibroblast transformation and since this effect was not transferable by EVs or soluble factors, HeC may alleviate acute myocardial damage, but may not have prolonged effect on long-term fibrosis or on post-ischemic revascularization.

University and Doctoral School

Semmelweis University, Doctoral School of Pharmaceutical Sciences

Supervisor

Dr. Zoltán Giricz

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

5976

Start

12:05

End

12:20

Authors (legacy)

Csenger Kovácsházi2,†, Marek Jelemenský1,† , Kristína Ferenczyová1 , Monika Hofbauerová3,4, Bernadett Kiss2, Éva Pállinger5, Edit Buzás5, Ágnes Kittel6, Viktor Nabil Sayour2, Anikó Görbe2,7, Csilla Pelyhe2, Szabolcs Hambalkó2, Miroslav Barančík1, Péter Ferdinandy2,7, Monika Barteková1,8, Zoltán Giricz2,7


1 Institute for Heart Research, Centre of Experimental Medicine, Slovak Academy of Sciences, 84104 Bratislava, Slovakia; marek.jelemensky@savba.sk (M.J.); kristina.ferenczyova@savba.sk (K.F.); miroslav.barancik@savba.sk (Mi.B.); monika.bartekova@savba.sk (M.B.)
2 Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest, Hungary; giricz.zoltan@med.semmelweis-univ.hu
3 Institute of Physics, Slovak Academy of Sciences, Dúbravskáa cesta 9, SK-84511 Bratislava, Slovakia; monika.hofbauerova@savba.sk (M.H.)
4 Centre of excellence for advanced material application, Slovak Academy of Sciences, Dúbravská cesta 9, SK-84511 Bratislava, Slovakia; monika.hofbauerova@savba.sk (M.H.)
5 Semmelweis University, Department of Genetics, Cell- and Immunobiology, Budapest, Hungary; e-mail@e-mail.com
6 Institute of Experimental Medicine, Eötvös Loránd Research Network, Budapest, Hungary
7 Pharmahungary ltd., Szeged, Hungary; e-mail@e-mail.com
8 Institute of Physiology, Faculty of Medicine, Comenius University in Bratislava, 81372 Bratislava, Slovakia; monika.bartekova@savba.sk
† These authors contributed equally